Publication:
Meta-Analysis Design and Results in Real Life: Problem Solvers or Detour to Maze. A Critical Review of Meta-Analysis of DAPT Randomized Controlled Trials.

dc.contributor.authorNúñez Gil, Ivan J
dc.contributor.authorElizondo, Ainhoa
dc.contributor.authorGradari, Simona
dc.contributor.authorVillablanca, Pedro A
dc.contributor.authorBueno, Hector
dc.contributor.authorFeltes, Gisela
dc.contributor.authorQuirós, Alicia
dc.contributor.authorRamakrishna, Harish
dc.contributor.authorBoshra, Louka
dc.contributor.authorFernandez-Ortiz, Antonio
dc.contributor.funderFundación AstraZeneca
dc.contributor.funderInstituto de Salud Carlos III
dc.date.accessioned2020-11-05T11:22:28Z
dc.date.available2020-11-05T11:22:28Z
dc.date.issued2019
dc.description.abstractTherapeutic strategies - such as duration of dual antiplatelet therapy after coronary artery stenting - usually generate a large quantity of meta-analyses. The meta-analyses that include the same randomized clinical trials should produce similar results. Our aim in the study is to analyze the quality and to compare the results of meta-analyses focused on a controversial topic such as dual antiplatelet therapy after percutaneous coronary intervention. We searched all published meta-analyses published up to November 2015 (near DAPT trial publication) selecting those that included the same randomized clinical trials comparing patterns of briefer versus longer-term double antiplatelet therapy. Seventeen meta-analyses achieved our selection criteria. Of the seventeen analyzed, we identified seven (41.1%) based on the same ten randomized clinical trials (RCTs), yet their results varied widely. Many of the meta-analyses differed in only some minor aspect of the design (i.e. eligible studies, length of comparators and statistical methods used). Some authors differed in the number of patients participating in RCTs and even, despite reviewing the same underlying trials, only 2 of the 7 meta-analyses included the same number of patients. Meta-analyses around cardiovascular, all-cause or non-cardiovascular death differ frequently. In the DAPT duration setting, several meta-analyses have been recently published based on the same data, presenting several issues making it difficult to determine clear recommendations on certain points.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipIN receives research funding from Astrazeneca; has received minor consulting fees from Boston, Medtronic, Astrazeneca; and speaking fees or support for attending scientificmeetings fromBoehringer, Daiichi-Sankyo, Lilly, AstraZeneca and Pfizer. AE is Astrazeneca employee. HB receives research funding from the Instituto de Salud Carlos III (PIE16/00021), AstraZeneca, BMS, Janssen and Novartis; has received consulting fees from Abbott, AstraZeneca, Bayer, BMS-Pfizer, Novartis; and speaking fees or support for attending scientificmeetings from AstraZeneca, Bayer, BMS-Pfizer, Ferrer, Novartis, Servier and MEDSCAPE-the heart.og. The other authors pose no relevant disclosures regarding this manuscript.es_ES
dc.format.number10es_ES
dc.format.page897-906es_ES
dc.format.volume20es_ES
dc.identifier.citationCardiovasc Revasc Med. 2019; 20(10):897-906es_ES
dc.identifier.doi10.1016/j.carrev.2018.10.021es_ES
dc.identifier.issn1878-0938
dc.identifier.journalCardiovascular revascularization medicine : including molecular interventionses_ES
dc.identifier.pubmedID30527593es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11306
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PIE16/00021es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.carrev.2018.10.021es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Investigación Cardiovascular Traslacional Multidisciplinariaes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Imagen Cardiovascular y Estudios Poblacionaleses_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshMeta-Analysis as Topices_ES
dc.subject.meshPercutaneous Coronary Interventiones_ES
dc.subject.meshRandomized Controlled Trials as Topices_ES
dc.subject.meshResearch Designes_ES
dc.subject.meshCoronary Artery Diseasees_ES
dc.subject.meshData Accuracyes_ES
dc.subject.meshDrug Therapy, Combinationes_ES
dc.subject.meshHumanses_ES
dc.subject.meshPlatelet Aggregation Inhibitorses_ES
dc.subject.meshRisk Factorses_ES
dc.subject.meshTreatment Outcomees_ES
dc.titleMeta-Analysis Design and Results in Real Life: Problem Solvers or Detour to Maze. A Critical Review of Meta-Analysis of DAPT Randomized Controlled Trials.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionAMes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication4e417023-fc1f-41d2-8130-485f76466465
relation.isAuthorOfPublicationc247543c-ab71-441c-8eec-b54f56c6a1ff
relation.isAuthorOfPublication.latestForDiscovery4e417023-fc1f-41d2-8130-485f76466465

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Meta‐AnalysisDesignandResults_2019.pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format
Description:
Artículo